Biohackers Gear Up for Genome Editing
By Heidi Ledford,
Nature News
| 08. 26. 2015
Untitled Document
A complete lack of formal scientific training has not kept Johan Sosa from dabbling with one of the most powerful molecular-biology tools to come along in decades.
Sosa has already used CRISPR, a three-year-old technology that makes targeted modifications to DNA, in test-tube experiments. Next week, he hopes to try the method in yeast and, later, in the model plant Arabidopsis thaliana.
Hailed for its simplicity and versatility, CRISPR allows scientists to make specific changes to a gene’s sequence more easily than ever before. Researchers have used CRISPR to edit genes in everything from bacteria to human embryos; the technique holds the potential to erase genetic defects from family pedigrees plagued by inherited disease, treat cancer in unprecedented ways or grow human organs in pigs. One researcher has even proposed modifying the elephant genome to produce a cold-adapted replica of the long-extinct woolly mammoth.
Such feats are beyond the reach of do-it-yourself (DIY) ‘biohackers’, a growing community of amateur biologists who often work in community laboratories, which typically charge a recurring fee for...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...